LIBTAYO (cemiplimab) is a prescription medication used in the treatment of certain types of cancer. It is a type of immunotherapy known as a checkpoint inhibitor, specifically targeting the PD-1 (programmed death receptor-1) pathway, which is a mechanism that tumors use to hide from the immune system. By blocking this pathway, LIBTAYO helps the immune system to detect and fight cancer cells. It is primarily used for the treatment of patients with advanced skin cancers, such as metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) that are not suitable for curative surgery or radiation, and certain types of non-small cell lung cancer (NSCLC). The effectiveness of LIBTAYO in treating these cancers has made it a valuable option in the oncology field, offering hope to patients with few other treatment options. Like all medications, it can cause side effects, and its use is carefully considered by healthcare professionals.